Repligen Q4 2021 Earnings Report
Key Takeaways
Repligen reported record revenue of $186.5 million for Q4 2021, a 72% increase year-over-year. GAAP EPS increased to $0.50, while adjusted EPS reached $0.81. The company's strong performance was attributed to accelerated demand for its products and the impact of recent acquisitions.
Repligen's Q4 2021 revenue reached a record $186.5 million, representing 72% year-over-year growth.
The company's GAAP operating margin increased by 400 bps to 20.1%, while the adjusted operating margin rose by 490 bps to 30%.
GAAP fully diluted EPS increased to $0.50, compared to $0.36 in Q4 2020, and adjusted fully diluted EPS increased to $0.81, compared to $0.52 in Q4 2020.
Repligen completed the acquisition of BioFlex Solutions, a single-use fluid management component manufacturer.
Repligen
Repligen
Forward Guidance
Repligen expects total revenue to be in the range of $800-$830 million, reflecting overall revenue growth of 19%-24% as reported.
Positive Outlook
- Total revenue is expected to be in the range of $800-$830 million
- Overall revenue growth of 19%-24% as reported
- Revenue growth of 21%-26% at constant currency
- Organic growth of 18%-22%
- Adjusted (non-GAAP) income from operations is expected to be in the range of $234-$240 million.
Challenges Ahead
- Gross margin is expected to be 57%-58% on both a GAAP and non-GAAP basis.
- Income from operations is expected to be in the range of $184-190 million on a GAAP basis.
- Net income is expected to be in the range of $138-$143 million on a GAAP basis.
- Adjusted (non-GAAP) net income is expected to be in the range of $185-$190 million.
- Fully diluted GAAP EPS is expected to be in the range of $2.39-$2.48.